Small-Cell Lung Cancer
Overview
Small cell lung cancer (SCLC) is a fast-growing type of lung
cancer. It spreads much more quickly than non-small cell lung cancer. SCLC is
the most aggressive form of lung cancer. It usually starts in the breathing
tubes (bronchi) in the center of the chest. These tumors often spread rapidly
(metastasize) to other parts of the body, including the brain, liver, and bone.
Symptoms of SCLC include bloody sputum, chest pain, cough, loss of appetite,
weight loss and wheezing. Treatment includes surgery, radiation therapy and
chemotherapy.
Click here for sample report @ http://www.wiseguyreports.com/sample-request/1418391-small-cell-lung-cancer-pipeline-review-h1-2017
Small-Cell Lung Cancer Industry Major
Outlook
The Pharmaceutical and Healthcare latest pipeline guide
Small-Cell Lung Cancer - Pipeline Review, H1 2017, provides comprehensive
information on the therapeutics under development for Small-Cell Lung Cancer
(Oncology), complete with analysis by stage of development, drug target,
mechanism of action (MoA), route of administration (RoA) and molecule type. The
guide covers the descriptive pharmacological action of the therapeutics, its
complete research and development history and latest news and press releases.
The Small-Cell Lung Cancer (Oncology) pipeline guide also
reviews of key players involved in therapeutic development for Small-Cell Lung
Cancer and features dormant and discontinued projects. The guide covers
therapeutics under Development by Companies /Universities /Institutes, the
molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA
Filed, Preclinical and Discovery stages are 10, 41, 33, 2, 32 and 5
respectively. Similarly, the Universities portfolio in Phase II and Preclinical
stages comprises 1 and 2 molecules, respectively.
Small-Cell Lung Cancer (Oncology) pipeline guide helps in
identifying and tracking emerging players in the market and their portfolios,
enhances decision making capabilities and helps to create effective counter
strategies to gain competitive advantage. Additionally, various dynamic
tracking processes ensure that the most recent developments are captured on a
real time basis.
Small-Cell Lung Cancer - Competitive Analysis
Key players are making innovative
developments in Small-Cell Lung Cancer industry. The same will help in improving the market
performance. Heavy investments are made by major players in the R&D sector
Scope
- The pipeline guide provides a snapshot of the global
therapeutic landscape of Small-Cell Lung Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Small-Cell Lung Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Small-Cell Lung Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Small-Cell Lung Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Small-Cell Lung Cancer (Oncology)
- The pipeline guide reviews pipeline therapeutics for Small-Cell Lung Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Small-Cell Lung Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Small-Cell Lung Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Small-Cell Lung Cancer (Oncology)
.Continued
For Detailed Reading Please visit @
https://www.wiseguyreports.com/reports/1418391-small-cell-lung-cancer-pipeline-review-h1-2017
About Us
Wise Guy Reports is part of the Wise Guy Consultants Pvt.
Ltd. and offers premium progressive statistical surveying, market research
reports, analysis & forecast data for industries and governments around the
globe. Wise Guy Reports understand how essential statistical surveying
information is for your organization or association. Therefore, we have
associated with the top publishers and research firms all specialized in
specific domains, ensuring you will receive the most reliable and up to date
research data available.
Contact Us:
NORAH TRENT
Partner Relations & Marketing Manager
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
No comments:
Post a Comment